Asian Pacific Journal of Cancer Prevention · 2013 · 42 citations · 18 references
MedicineOncologyUrologyGenitourinary OncologyMolecular OncologyUrologic OncologyBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyBladder CancerUrinary CytologyUrologic Cancer DiagnosisBladder Cancer DiagnosisBladder Cancer Recurrence BiomarkersBladder PathologyControlsEarly DiagnosisPositive ControlsUrinary Bladder Tumor DetectionUrine Cytology Markers
BACKGROUND: Early diagnosis of carcinoma of bladder remains a challenge. Survivin, a member of the inhibitor of apoptosis (IAP) protein family, is frequently activated in bladder carcinoma. The objective of this study was to investigate urinary survivin as a marker for diagnosis of urinary bladder. MATERIALS AND METHODS: We examined urinary survivin concentration in 28 healthy individuals, 46 positive controls and 117 cases of histologically proven TCC prior to transurethral resection, using ELISA, and compared values with findings for urinary cytology. RESULTS: Survivin was found to be significantly higher in the cancer group (P<0.05). A cut off value of 17.7 pg/ml was proposed, with an approximate sensitivity of 82.9% and specificity of 81.1% (P<0.0001), whereas urine cytology had a sensitivity of 66.7% and a specificity of 96.0%. CONCLUSIONS: Urinary survivin can be used as a non-invasive diagnostic biomarker for TCC bladder, both for primary and recurrent disease.
18
Rebecca L. Siegel, Elizabeth Ward, Otis W. Brawley et al. · CA A Cancer Journal for Clinicians · 2011 · 4.1K citations · Full text
Statistics review 13: receiver operating characteristic curves.
Viv Bewick, Liz Cheek, Jonathan Ball · Critical Care · 2004 · 790 citations · Full text
Urine Detection of Survivin and Diagnosis of Bladder Cancer
Shannon D. Smith · JAMA · 2001 · 283 citations